All News | RheumNow

All News

RheumNow Podcast square

What is Colchicine Worth? (6.23.2023)

Save

d Jack Cush, MD

Jun 22, 2023

Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?

Read Article

price%20of%20pills.jpg

Why Patients Don't Take Medicines

Save

d CDC

Jun 22, 2023

About 60% of adults aged 18 and over reported taking at least one prescription medication in 2021, with 36% reporting taking three or more. Out-of-pocket costs on retail drugs rose 4.8% to $63 billion in 2021.

Read Article

FDA,approved,stamp,blue

FDA Approves Colchicine for CV Prevention

Save

d Jack Cush, MD

Jun 22, 2023

The FDA has approved colchicine (Lodoco) for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such an indication.

Read Article

Biologic.choice.MD_.jpeg (keep)

Treatment Sequences Define Subphenotypes in RA Patients

Save

d Jack Cush, MD

Jun 21, 2023

An analysis of a large rheumatoid arthritis cohort sheds light on biologic disease-modifying anti-rheumatic drugs (bDMARDs) clustering that may be used in management, as certain clusters of b/tsDMARD correlated with disease activity over time.

Read Article

Abatacept Safety Outcomes Across 7 European Registries A multinational registry analysis of RA receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy. https://t.co/CVeAV0ZXA8 https://t.co/A8McLt0rSl

Links:

https://bit.ly/43SFQN4

Dr. John Cush RheumNow ( View Tweet)

Jun 22, 2023

2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis These included 5 overarching principles & 10 recos on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA. https://t.co/OaRBNfhNCJ https://t.co/gF9QFDYTsu

Links:

https://bit.ly/3CGNiPG

Dr. John Cush RheumNow ( View Tweet)

Jun 22, 2023

Uncertainty can be worrisome. When uncertainty lies ahead, optimism and preparation are your best navigators. Im an optimist. https://t.co/JNzWJFMEfV https://t.co/ltIdy6hNqn

Links:

https://bit.ly/3NGTNrY

Dr. John Cush RheumNow ( View Tweet)

Jun 22, 2023

Medicare and Commercial claims analysis shows 1 #RA pts at risk for H Zoster 2 RA + HZ = more Hospitalizations & ED visits, esp in 30d after HZ 3 Higher total costsalso higher in month after HZ https://t.co/gFlsLDIxVB https://t.co/733W3Kv3WC

Links:

https://bit.ly/46gdvSr

Dr. John Cush RheumNow ( View Tweet)

Jun 22, 2023

Study of 28,360 #PsA pts shows blacks have signif more HTN (59 v 52%), DM (31 v 23%), obesity (47 v 30%), gout (12 v 8%); while whites have more cancer (20 v 16%), anxiety (28 v 23%) & OP (14 v 12). Rx (NSAIDs, TNFi, DMARDs) also unequal by race. https://t.co/Ok7vhTdS8g https://t.co/ozFIg9HNuy

Links:

https://bit.ly/42WjRUn

Dr. John Cush RheumNow ( View Tweet)

Jun 22, 2023

Arborviral infx w/ rituximab? 21 RTX pts dx w/ arboviral neuroinvasive Dz, (encephalitis, acute flaccid myelitis); 79% died. B cell depletion impairs immunity & spread of West Nile Virus, serologic Ab Dx tests; thus if suspected, order RT-PCR tests https://t.co/yQiXI2IYqd https://t.co/dZX2CQJs0L

Links:

https://wb.md/3qX08GG

Dr. John Cush RheumNow ( View Tweet)

Jun 22, 2023

Small study 57 EGPA pts shows using MTX or AZA to be equipotent as 1st or 2nd line therapy in EGPA. MTX pts used more cumulative steroids (6 g vs 10.7 g @5 yrs) & more AE (66% vs 30%); AZA had fewer asthma/ENT relapses (23% vs 64%, p= 0.04) https://t.co/WZHudojrzk https://t.co/X6xITcQtCw

Links:

https://bit.ly/43Mw4w9

Dr. John Cush RheumNow ( View Tweet)

Jun 22, 2023

Predictors of DAPSA28 remission in #PsA starting 1st TNF-inhibitor (13 369 bio-naive pts from 13 Euro registries) showed 6 mo remission 25% and 12 retention 63%. Remission predictors: younger age, Dz duration, males (OR 1.85), CRP >10 (OR 1.52) https://t.co/cTefy6xeUB https://t.co/b2Ok6HJgE1

Links:

https://bit.ly/3p3hvFq

Dr. John Cush RheumNow ( View Tweet)

Jun 22, 2023

HRT for RA? Not Yet Dr. Aurelie Najm discusses OP0268 presented at EULAR 2023 in Milan, Italy. @AurelieRheumo https://t.co/hoyZ2Ezn4G https://t.co/XWfE1RHwpi

Links:

https://bit.ly/3PtetVo

Dr. John Cush RheumNow ( View Tweet)

Jun 22, 2023

Abatacept Safety Outcomes Across 7 European Registries A multinational registry analysis of rheumatoid arthritis receiving abatacept has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy. https://t.co/XcOSLTgQVR https://t.co/ZfwAA0baRM

Links:

https://bit.ly/3N8dA1K

Dr. John Cush RheumNow ( View Tweet)

Jun 21, 2023

2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis These included 5 overarching principles & 10 recommendations on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA. https://t.co/5WoIm8OPZs https://t.co/xqNxDvuymJ

Links:

https://bit.ly/3NAo3Vm

Dr. John Cush RheumNow ( View Tweet)

Jun 21, 2023

RheumNow’s newly launched Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available. https://t.co/0dV23VPDQH https://t.co/HfKhji40vU

Links:

https://bit.ly/3Jo1bWq

Dr. John Cush RheumNow ( View Tweet)

Jun 21, 2023

Watch: Should you Assess Rheumatoid Factor Serially? Dr. Jack Cush discusses abstract OP0272 at EULAR 2023 in Milan, Italy. https://t.co/5e4SiPGDUM https://t.co/CzE597Auwg

Links:

https://bit.ly/43OJ3NR

Dr. John Cush RheumNow ( View Tweet)

Jun 21, 2023

Watch: De Novo Renal Nephritis Flares During Belimumab Trials Drs. Yuz Yusof and Iaonnis Parodis discuss abstract POS1156 at EULAR 2023 in Milan, Italy. https://t.co/XLzDF2VZ7Q https://t.co/iE16Ag3Rsu

Links:

https://bit.ly/3CCubWF

Dr. John Cush RheumNow ( View Tweet)

Jun 21, 2023

How Often Do You Monitor MTX? Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening. https://t.co/niPFjQTenh https://t.co/JyL8t6EexT

Links:

https://bit.ly/3CUTNyt

Dr. John Cush RheumNow ( View Tweet)

Jun 20, 2023

Pediatric Rheumatologist Loan assistance repayment program from HSRA. A loan assistance of up to $100,000 to eligible pediatric medical subspecialists in exchange for a 3-year, full-time service commitment at an approved facility in an underserved area https://t.co/6oFkEEKAY9

Links:

https://bit.ly/3PnGGgr

Dr. John Cush RheumNow ( View Tweet)

Jun 20, 2023

×